IPX · IperionX Limited

The thesis

IperionX's titanium-powder business has no revenue and no financing for its Titan mine, so the shares are more likely to lag the S&P 500 over the next three months than to beat it. The September-quarter cash report, due to the ASX by about 31 October 2026, settles whether US Army cash and pilot output turn into customer receipts.

The shares closed at $14.50 on 27 October 2026, 75.9% below the $60.11 52-week high and 32.7% lower over three months, according to adjusted daily closes. The 14-day relative strength index (RSI) was 42.8, up from 24.7 on 14 October 2026, so the extreme selling has eased. The narrative is saturated: coverage centres on the price decline, the loss and funding, and no new September-quarter filing had been located by 28 October 2026.

The engineering case is intact. The FY26 annual report (Form 20-F, filed 29 September 2026) shows a US$66.8M net loss, no revenue in FY26 or the four prior years, and no secured financing for Titan.

Bullish and bearish views on IperionX Limited

The bull case on IperionX Limited (IPX), in brief: Army funding is contractual. The bear case: No revenue after five years.

Bull case

• Army funding is contractual. IperionX's 31 August 2026 release stated US$11.5M funded and obligated under Task Order 2, against a US$18.5M base value and a US$25.4M maximum with unexercised options.
• Processing data improved. The company's 16 September 2026 Form 6-K reported GenX continuous runs at six times the volume of the batch process and over 75% lower power use per kilogram across four campaigns.
• Analyst targets sit far above the price. MarketBeat (14 October 2026) listed six buy ratings and one sell, with an average target of $42.00. Roth Capital's target is $53 and B. Riley kept a Buy rating with a $34 target on 30 September 2026.
• Insiders bought in July. MarketBeat reported open-market purchases by Chairman Todd Hannigan and CEO Anastasios Arima in July 2026, around the $21.98 ADS placement.
• Selling pressure has eased. The RSI rose to 42.8 at the 27 October 2026 close from 24.7 on 14 October 2026, and the close of $14.50 is above the $14.00 level broken in mid-October.

Bear case

• No revenue after five years. The 20-F filed 29 September 2026 reports zero revenue in FY26 and the four prior years. The June 2026 quarterly report showed customer receipts of US$8 thousand in the quarter.
• Titan financing is open. The 20-F says mine-development financing is not secured. The 4 June 2026 feasibility study put development capital at US$381.3M, against US$35.2M of cash at 30 June 2026 and about US$84M pro forma for the July raise.
• Cash burn is steady. The June 2026 quarterly report showed operating cash outflow of US$11.9M in the quarter and US$45.0M for FY26.
• Further dilution would come on weaker terms. The 8 July 2026 placement of 2,275,000 American depositary shares (ADS) at $21.98 raised US$50M. The 27 October 2026 close of $14.50 is well below that price.
• Moving averages sit far above the price. MarketBeat (14 October 2026) put the 50-day moving average at $20.48 and the 200-day at $27.20. The shares set a 52-week low of $14.60 intraday that day.
• Control history. The 20-F notes past material weaknesses in internal controls. Law firms have investigated the March 2026 right-of-use restatement since March; the shares fell 27.4% over two sessions to $29.44 on 16 March 2026.

Price setup

Adjusted daily closes show $14.50 on 27 October 2026, against $13.98 on 14 October 2026 and $15.82 on 1 October 2026. The shares trade 75.9% below the $60.11 52-week high.

The price is far under the 50-day ($20.48) and 200-day ($27.20) moving averages reported by MarketBeat on 14 October 2026. Any recovery to those averages would be a large move from the current level. The July placement price of $21.98 is the nearest reference above the market that investors in the raise hold.

Crowding evidence is limited. The shares carry no sign of heavy retail buying at present, and analyst targets have been cut rather than raised since September. The one dated event close at hand is the quarterly cash report.

Catalysts, next 30 days

• Undated: notice of meeting for the Texas redomiciliation. The 20-F gave no meeting date. A filed notice would make the move to Nasdaq common stock a datable event.

Elapsed catalysts

• ~31 October 2026, est.: September-quarter cash report. The ASX deadline is 31 October. It is the first report that can show Task Order 2 receipts, GenX output and cash burn after the July raise. (passed 6d ago)
• Undated: Titan financing announcement. None had been announced by 28 October 2026. Any terms would show how much dilution the US$381.3M capital need implies. (passed 9d ago)

What would change the view

The case breaks if the September-quarter report shows customer receipts still near zero, a delayed output target, or cash falling faster than the roughly US$12M quarterly outflow seen in June. It also breaks on a second equity raise priced below the $21.98 July level, or a filed class action over the restatement.

On price, a daily close below $12.00 would extend the October break below $14.00 and $13.98. Evidence that would lift the rating is a report with material Army receipts, a funded path for Titan, or a financing on terms above the current share price.

What it trades with

IperionX trades on US critical-materials and defense-supply-chain sentiment, and on Army and Department of Defense funding news. Its Australian listing means US sessions open against overnight ASX pricing.

Moves in the shares have followed company-specific events, including the March restatement, the July raise and the September analyst cuts, more than sector moves. No sample large enough to measure sector correlation is available here.